Health on the Water: Cardiol Therapeutics Anti-Inflammatory Innovation

Initiating Coverage: Cardiol Therapeutics (NASDAQ: CRDL)

First Look Equities has initiated corporate visibility coverage on Cardiol Therapeutics (NASDAQ: CRDL). As a clinical-stage biotechnology company, Cardiol is dedicated to the development of innovative, targeted anti-inflammatory therapies for cardiovascular diseases. Their lead product candidate, CardiolRx™, is a pharmaceutically manufactured oral formulation of cannabidiol designed to target inflammatory pathways in the heart. This coverage initiation represents our ongoing commitment to showcasing companies whose work holds potential for health, wellness, and cardiac safety — both on land and on the water.

Cardiovascular health is the ultimate asset, particularly for active, high-performance executives. Whether navigating corporate boardrooms or high-seas journeys, cardiac wellness is a primary pillar of longevity. Our 'Health on the Water' series highlights companies that are pioneering new treatments for inflammatory heart conditions. In conjunction with this coverage initiation, First Look Equities coordinates exclusive, private boardroom charters and strategic roadshow events on our partner 102' Leopard yacht in Miami. This program provides Cardiol's executive leadership with a premium, secure environment to present their clinical milestones directly to qualified capital allocators.

IMPORTANT COMPLIANCE NOTICE: First Look Equities is a marketing and visibility platform. We do not provide investment advice, buy/sell recommendations, stock valuations, or target prices. Our work is strictly focused on initiating visibility coverage to expand market awareness. All capital-markets materials and presentations are prepared in collaboration with the issuer and are for informational purposes only. We do not solicit investments or offer securities of any kind.

Clinical Focus: Addressing Inflammatory Heart Disease

Cardiol's clinical pipeline is centered on two major orphan heart diseases where inflammation plays a critical, destructive role: recurrent pericarditis and acute myocarditis. Pericarditis is an inflammation of the pericardium (the sac surrounding the heart), which causes debilitating, sharp chest pain and frequently leads to emergency room visits. Recurrent pericarditis is notoriously difficult to manage, with patients often suffering from multiple painful episodes that severely impact their quality of life. Cardiol's Phase II MAVERIC-Pilot study has recently reported positive top-line data, showing a statistically significant and clinically meaningful reduction in pericarditis pain and inflammation markers (such as C-reactive protein) during the treatment period.

Acute myocarditis is an inflammation of the heart muscle (myocardium) that can lead to rapid-onset heart failure or life-threatening arrhythmias. It is one of the leading causes of sudden cardiac death in young, active individuals and athletes. Currently, there are no FDA-approved therapies specifically indicated for the treatment of acute myocarditis. Cardiol is currently conducting the Phase II ARCHER trial, a multi-center, double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of CardiolRx™ in patients presenting with acute myocarditis. By targeting the inflammasome pathways that drive myocardial damage, Cardiol aims to prevent long-term heart failure and improve patient recovery.

Private Boardrooms and Executive Roadshows on the Water

At First Look Equities, we believe that high-impact stories require high-impact settings. For the select companies we initiate coverage on, we coordinate executive boardrooms and private roadshow charters in Miami, Florida. The program, hosted in partnership with Luxury Miami Co., utilizes a pristine 102' Leopard yacht to compress weeks of scattered scheduling into a single, high-conviction afternoon. Cardiol Therapeutics' leadership is invited to leverage this custom-tailored floating boardroom to conduct strategic presentations and align with key capital allocators.

This private roadshow environment is engineered to provide absolute privacy, comfort, and state-of-the-art presentation capabilities. It combines white-glove Fontainebleau basecamp logistics, private tarmac transit, and premium marine amenities. By conducting meetings on the water, companies can cut through the noise of traditional roadshows, creating a memorable, dedicated space where their equity story receives undivided attention. Initiating coverage is the first step; bringing the story to life in a premium physical setting is the execution.